I
Imagene AI
AI-based molecular testing for cancer
About Imagene AI
Imagene AI operates within the digital pathology and precision medicine sectors, offering an AI-powered platform that delivers real-time molecular intelligence from digitized biopsy images. The company's core technology is a foundation model trained on over 1.5 million pathology slides, which facilitates the rapid profiling of a wide range of biomarkers for cancer.
Read full description
This capability aims to significantly reduce the time required for patient diagnosis and treatment matching, which traditionally takes several weeks. By providing immediate molecular insights, the platform supports healthcare providers in making timely and informed decisions for precision oncology. The business model is structured as a Software as a Service (SaaS), providing adaptive capabilities for biomarker discovery and patient identification to its clients, which primarily include pharmaceutical companies and healthcare providers.
Recent funding rounds, including a significant Series B investment, underscore investor confidence in the company's approach to transforming cancer diagnostics and treatment. The platform's ability to function as a tool for precision medicine places it at the intersection of AI development and clinical application in oncology.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 38
- Open positions
- 4
- Dealroom signal
- 85.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Precision Medicine, Biotech and Pharma, Techbio, Hard Tech, Techbio Drug Discovery, Digital Pharma
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2025 | $23M | $92M | Larry Ellison | ↗ |
| SERIES A✓Equity / VC | May 2022 | $19M | $74M | Eyal Gura · David B. Agus · Larry Ellison | ↗ |
Growth signals
Latest recorded traffic for Imagene AI is 6.3K monthly website visits, up 80% over the last three months. Imagene AI's team grew 8.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A3 investors entered at this stage
Eyal Gura
David B. Agus
Larry Ellison
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Imagene AI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Imagene AI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.